Review
Oncology
Izabela Zarebska, Maciej Harat
Summary: Stereotactic body radiotherapy (SBRT), also known as stereotactic ablative radiotherapy (SABR), is commonly used in inoperable patients with early-stage non-small lung cancer (NSCLC). This review summarizes the evidence of dose-fractionation in SBRT of NSCLC patients in various locations, highlighting the increased risk of severe toxicity in lesions located close to structures such as the bronchial tree or mediastinum.
Article
Oncology
Bong Kyung Bae, Kyungmi Yang, Jae Myung Noh, Hongryull Pyo, Yong Chan Ahn
Summary: This study reports the clinical outcomes of proton and photon stereotactic body radiation therapy (SBRT) for early-stage lung cancer. The findings suggest that proton SBRT may be considered for patients at high risk of developing radiation pneumonitis, as it showed comparable oncologic outcomes and toxicity profiles to photon SBRT.
Article
Multidisciplinary Sciences
Arta M. Monjazeb, Megan E. Daly, Guillaume Luxardi, Emanual Maverakis, Alexander A. Merleev, Alina I. Marusina, Alexander Borowsky, Amin Mirhadi, Stephen L. Shiao, Laurel Beckett, Shuai Chen, David Eastham, Tianhong Li, Logan V. Vick, Heather M. Mcgee, Frances Lara, Leslie Garcia, Leigh Anne Morris, Robert J. Canter, Jonathan W. Riess, Kurt A. Schalper, William J. Murphy, Karen Kelly
Summary: Stereotactic ablative radiotherapy (SABR) is a standard-of-care for medically-inoperable-early-stage non-small cell lung cancer (NSCLC). A phase I study tested the addition of atezolizumab to SABR in high risk, medically inoperable, early-stage NSCLC, and found that it was well tolerated and showed efficacy signals.
NATURE COMMUNICATIONS
(2023)
Article
Immunology
Lirong Wu, Jun Zhu, Nils-Petter Rudqvist, James Welsh, Percy Lee, Zhongxing Liao, Ting Xu, Ming Jiang, Xiangzhi Zhu, Xuan Pan, Pansong Li, Zhipeng Zhou, Xia He, Rong Yin, Jifeng Feng
Summary: This study evaluated the T cell receptor (TCR) repertoire before and after stereotactic body radiotherapy (SBRT) for early-stage non-small-cell lung cancer (NSCLC). The analysis showed that quantitative assessments of TCRs can help predict prognosis in NSCLC patients. Patients who had a lower change in Shannon Entropy in TCR repertoire after SBRT had poorer metastasis-free survival, indicating a potential correlation between immune function and treatment outcomes.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Critical Care Medicine
Yusef A. Syed, William Stokes, Manali Rupji, Yuan Liu, Onkar Khullar, Nikhil Sebastian, Kristin Higgins, Jeffrey D. Bradley, Walter J. Curran, Suresh Ramalingam, James Taylor, Manu Sancheti, Felix Fernandez, Drew Moghanaki
Summary: Facilities with higher use of SBRT for surgery in patients with early stage NSCLC showed lower rates of postoperative mortality. These findings suggest that the availability and use of SBRT may improve the selection of patients predicted to be at high risk of postoperative mortality.
Article
Oncology
Gang Liu, Lewei Zhao, An Qin, Inga Grills, Rohan Deraniyagala, Craig Stevens, Sheng Zhang, Di Yan, Xiaoqiang Li, Xuanfeng Ding
Summary: The study developed a 4D interplay effect model to evaluate the effectiveness of using spot-scanning proton arc (SPArc) therapy for hypo-fractionated lung SBRT. Results showed that SPArc was more effective in mitigating interplay effects and sparing normal tissue compared to other proton therapy techniques. The study concluded that SPArc may make proton SBRT delivery more feasible and less complex.
FRONTIERS IN ONCOLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
Syed S. Razi, Karishma Kodia, Ahmed Alnajar, Mark Block, Francisco Tarrazzi, Dao Nguyen, Nestor Villamizar
Summary: In patients aged 80 years or older with stage I NSCLC, lobectomy offers better survival outcomes compared to SBRT, especially in those with no comorbidities. The number of lymph nodes examined during lobectomy, as well as age, sex, high grade, and tumor size, were found to be independent predictors of survival.
ANNALS OF THORACIC SURGERY
(2021)
Article
Oncology
Eleni Gkika, Elke Firat, Sonja Adebahr, Erika Graf, Ilinca Popp, Gianluca Radicioni, Simon S. Lo, Ursula Nestle, Nils H. Nicolay, Gabriele Niedermann, Dan G. Duda, Anca-L. Grosu
Summary: We conducted a prospective study to investigate the changes in circulating immune cells after stereotactic body radiotherapy (SBRT) in early-stage NSCLC patients. We found no significant increase in CD8(+) cytotoxic T lymphocytes at the first follow-up, but observed a significant expansion in Ki-67(+)CD8(+) and Ki-67(+)CD4(+) T-cell fractions in patients receiving 10 Gy or less per fraction. Our findings suggest that SBRT can induce immediate expansion of circulating effector T-cells.
NPJ PRECISION ONCOLOGY
(2023)
Article
Oncology
Mihailo Miljanic, Chika Nwachukwu, Assal Rahimi
Summary: This case series and literature review suggest that definitive ablative radiation therapy may serve as a safe and effective treatment option for non-operable patients with early stage breast cancer. The observed durable treatment responses and minimal toxicity support the potential of this approach.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Mihailo Miljanic, Chika Nwachukwu, Assal Rahimi
Summary: This case series and literature review investigate the efficacy and safety of definitive ablative radiation therapy for non-operable patients with early stage breast cancer. The two cases presented demonstrate the potential of this approach to achieve durable responses.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Johannes Uhlig, Sumarth Mehta, Meaghan Dendy Case, Andrew Dhanasopon, Justin Blasberg, Robert J. Homer, Stephen B. Solomon, Hyun S. Kim
Summary: The study found that the overall survival following TA and SBRT for stage I lung cancer is comparable for most histological subtypes, except for non-small cell NETs where TA showed longer overall survival.
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY
(2021)
Article
Oncology
Rogier Baak, Francois E. J. A. Willemssen, Yvette van Norden, Ferry A. L. M. Eskens, Maaike T. W. Milder, Ben J. M. Heijmen, Bas Groot Koerkamp, Dave Sprengers, Lydi M. J. W. van Driel, Heinz-Josef Klumpen, Wilhelm den Toom, Merel S. Koedijk, Jan N. M. IJzermans, Alejandra Mendez Romero
Summary: This study examined the feasibility and safety of adding SBRT treatment in patients with unresectable perihilar cholangiocarcinoma, showing promising results in terms of local control and overall survival. However, further evaluation in a larger patient population is recommended due to the small sample size in this study.
Article
Oncology
Zhe Chen, Hotaka Nonaka, Hiroshi Onishi, Eiji Nakatani, Mitsuhiko Oguri, Masahide Saito, Shinichi Aoki, Kan Marino, Takafumi Komiyama, Kengo Kuriyama, Masayuki Araya, Licht Tominaga, Ryo Saito, Yoshiyasu Maehata, Ryoji Shinohara
Summary: This study investigated the relationship between systemic autoimmune diseases (SADs) and stereotactic body radiation therapy (SBRT) in patients with stage I non-small cell lung cancer (NSCLC). The findings showed that NSCLC patients with SADs had a poorer prognosis compared to the control group, but had an equal incidence rate of radiation pneumonitis after SBRT. Therefore, SBRT should be considered as a radical treatment for stage I NSCLC patients with SADs, but the associated poor prognosis should be kept in mind.
Article
Oncology
Mingdi Zhang, Kejin Wu, Peng Zhang, Maoli Wang, Fang Bai, Hongliang Chen
Summary: BCS shows independent favorable prognostic factor and can be acceptable and preferable alternative to mastectomy for well-selected early-stage T1 or T2 CLBC patients.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Oncology
Casey Moore, Ching-Cheng Hsu, Wei-Min Chen, Benjamin P. C. Chen, Chuanhui Han, Michael Story, Todd Aguilera, Laurentiu M. Pop, Raquibul Hannan, Yang-Xin Fu, Debabrata Saha, Robert Timmerman
Summary: Combining radiation with immunotherapy can harness immune-stimulatory effects for better tumor treatment outcomes. Factors such as immunotherapy and radiation dose sequencing, as well as radiation fraction spacing, impact the response to combination therapy. Personalized PULSAR-style radiation dosing shows better tumor control in this model, emphasizing the importance of preclinical investigation in designing clinical trials for combination therapy.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)